T-cell clones with the T4 phenotype were established from patients with tuberculoid leprosy. The antigen reactivity of these clones ranged from stringent specificity for Mycobacterium leprae to broad cross-reactivity with other mycobacteria. Killed M. leprae had a weak stimulatory capacity which could be enhanced by ultrasonication. Among the three candidate antileprosy vaccines, M. leprae, M. bovis BCG, and the ICRC (Indian Cancer Research Center) strain, the last was superior in stimulating cross-reactive T4 clones. This finding argues for a differential masking of similar or identical membrane antigens in various mycobacterial species. T-cell clones with defined reactivity patterns for mycobacterial antigens could be helpful tools for the characterization of an antileprosy vaccine.
Leprosy is a chronic infectious disease caused by the intracellularly growing bacterium Mycobacteriuim leprae (3, 6, 12) . It has been estimated that 15 million cases exist worldwide; this is considered a major health problem, particularly because of the extreme stigma and fear associated with this disease. Although leprosy can be treated chemotherapeutically, it has become clear that a satisfactory control of the disease will ultimately depend on active vaccination (3; T. H. Maugh II, Science 215: 1083, 1982) .
The rational design of a potent antileprosy vaccine will depend on prior identification of microorganisms or proteins sharing protective epitopes with M. leprae. Identification of relevant antigens must be accomplished with T cells, owing to the exclusive role of T cells in protection (3, 6, 12 ). This has now become possible at the single-cell level because recent advances in tissue culture technology have allowed the propagation of monoclonal T cells which retain antigen specificity, phenotype, and biological function. Using this technology, we established and characterized T-cell clones with the helper/inducer phenotype from patients with tuberculoid leprosy and used these T-cell clones as tools in the functional analysis of antigenic relatedness at the T-cell level between various mycobacterial strains. M. leprae (Fig. 1) (3, 11) . Our clonal approach revealed that the T-cell response of leprosy patients is heterogeneous and encompasses not only cross-reactive but also M. leprae-specific T-cell populations. Therefore, the use of a panel of T-cell clones with various reactivity patterns will markedly improve the classification of mycobacterial species and strains according to their relatedness with M. leprae antigens at the T-cell level.
MATERIALS AND METHODS
Based on histopathological findings, leprosy can be divided into two main stages. At the one pole (tuberculoid leprosy), patients have efficient specific T-cell immunity capable of limiting bacterial growth, whereas at the other pole (lepromatous leprosy), specific T-cell immunity is markedly impaired and unable to control the multiplication of the microorganisms. Recent studies with T cells from leprosy patients have shed some light on the role of helper/inducer T4+ cells in this disease.
In lepromatous, but not in tuberculoid, leprosy the following observations, which point to a quantitative defect in the T4-cell population, have been made: (i) in lesions, the T4/T8 cell ratio is drastically reduced (25) ; (ii) antigen-induced IL-2 and IFN--y secretion is markedly impaired (13, 18) ; and (iii) IFN--y secretion-at least partially-can be restored by exogenous IL-2 (13, 18) . Taken together, these data indicate that T4+ lymphocytes capable of secreting IFN--y after antigenic stimulation play an important role in acquired resistance to M. Ieprae. Our T-cell clones expressed the T4+ phenotype, and produced IFN in cultures with antigen and accessory cells. Clone 3B3 produced IFN only in the presence of additional exogenous IL-2. Although not formally proven, the dependence of T cells on IL-2 indicates that IFN was produced by the T-cell clones and belonged to the IFN--y class, which is known to be a potent mediator of macrophage activation (e.g., reference 21). We therefore suggest that our clones were derived from a T-cell population relevant to protection against M. leprae. Consequently, these T-cell clones were used as tools for the functional characterization of candidate vaccines, since no other procedures are available at present to analyze the capacity of antigen preparations to stimulate T-cell immunity at the preclinical level.
In developing a vaccination strategy against leprosy, the following approaches are currently being considered [2, 3, (2, 3, 5) . Besides BCG, the ICRC strain is another in vitro cultivable candidate vaccine against leprosy. This strain has been found to convert lepromin skin test-negative individuals (lepromatous leprosy patients and household contacts) into skin testpositive cases (9) and is currently being tested in an antileprosy vaccination trial in India. Another approach to vaccination would be the use of killed M. leprae, since it has been shown that even in the absence of an adjuvant killed M.
leprae can induce cellular immune responses in experimentally infected animals (15, 16, 19, 22) .
A comparison of the antigenicity of the three candidate vaccines, M. leprae, BCG, and the ICRC strain, with that of our M. leprae protein-reactive human T-cell clones revealed the following ranking order with respect to their capacity to stimulate human T cells in undegradated form: the ICRC strain > BCG > M. leprae. The ICRC vaccine seems to be processed or presented by normal human accessory cells in a more efficient way than the BCG and M. leprae vaccines. This finding would favor the use of the ICRC strain as an antileprosy vaccine to stimulate cross-reactive T cells. Since we detected T-cell clones with exclusive specificity for M. leprae, it might be interesting to evaluate their particular contribution to protection.
It is anticipated that a functional analysis of antigenic relatedness with T-cell clones as probes will have a great potential for the rational design of vaccines against bacterial and parasitic diseases in which protection is predominantly governed by T cells. This approach will gain particular importance once recombinant proteins become available for the construction of a novel generation of vaccines (7, 26) . We plan to use our panel of M. leprae-reactive T-cell clones to characterize distinct proteins or peptides with respect to their capacity to stimulate helper/inducer T cells.
